SUZANNA FULLER: Open Payments
NPI 1326504382 · NACOGDOCHES, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$487 in 23 payments from 12 companies in 2025. Trend: 2023 $174 · 2024 $532 · 2025 $487
Food & beverage: $442Education: $45
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $96 |
| Novo Nordisk Inc | 4 | $85 |
| Lilly USA, LLC | 1 | $45 |
| AstraZeneca Pharmaceuticals LP | 2 | $37 |
| Dexcom, Inc. | 2 | $37 |
| Antares Pharma, Inc. | 2 | $36 |
| Boston Scientific Corporation | 1 | $31 |
| GlaxoSmithKline, LLC. | 2 | $30 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $30 |
| GENZYME CORPORATION | 1 | $22 |
Products named: CAPLYTA, Wegovy, FARXIGA, Dexcom G6 Transmitter, XYOSTED, WATCHMAN FLX, TRELEGY ELLIPTA, XIFAXAN.
Industry payments across TX — which companies pay providers there.
